19 unchanged sentences
S&P Pharmaceuticals Select Index (^SPSIPH) $ 100.00 $ 88.76 $ 78.82 $ 79.90 $ 82.47 $ 107.22
−Removed: Pacira BioSciences, Inc.
−Removed: | 2024 Annual Report on Form 10-K | Page 73
Dividend Policy
We have never declared or paid any dividends on our common stock.
−Removed: We currently intend to retain any future earnings to finance the future development and expansion of our business, and as such we do not expect to pay any dividends on our common stock in the foreseeable future.
+Added: We currently intend to retain any future earnings to finance the future development and expansion of our business, and as such we do not expect to pay any dividends on our
+Added: Pacira BioSciences, Inc.
+Added: | 2025 Annual Report on Form 10-K | 77
+Added: common stock in the foreseeable future.
The payment of any future dividends would be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in the agreements governing our indebtedness, provisions of applicable law and any other factors our board of directors deems relevant.
Purchases of Equity Securities by the Registrant
+Added: The following table provides information on our share repurchases during the quarter ended December 31, 2025:
+Added: Issuer Purchases of Equity Securities
+Added: Period Total Number
+Added: of Shares Purchased Average Price
+Added: Paid Per Share (1)
+Added: Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)
+Added: Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (1)
+Added: October 1, 2025 – October 31, 2025 — $ — — $ 199,998,530
+Added: November 1, 2025 – November 30, 2025 768,164 $ 23.41 768,164 $ 182,014,229
+Added: December 1, 2025 –December 31, 2025 1,236,528 $ 25.89 1,236,528 $ 150,001,371
+Added: Total 2,004,692 $ 24.94 2,004,692 $ 150,001,371
+Added: (1) The average price paid per share excludes less than $0.1 million of broker fees and $1.0 million of excise tax incurred on share repurchases for the three months ended December 31, 2025.
+Added: The remaining authorization outstanding for repurchases of common stock also excludes broker fees and the excise tax incurred.
+Added: (2) Our Board of Directors has authorized the repurchase of common stock under a share repurchase program adopted and announced in April 2025.
+Added: The share repurchase program authorizes the Company to purchase up to an aggregate of $300.0 million of the Company’s outstanding common stock.
+Added: Repurchases under this program may be made at management’s discretion on the open market or through privately negotiated transactions, including plans that comply with Rule 10b5-1 under the Exchange Act.
+Added: The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026.
+Added: The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions.
+Added: Refer to Note 13, Stockholders’ Equity , to our consolidated financial statements included herein for more information on our share repurchases.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.